– The World Health Organisation (WHO) has resumed trials of the anti-malaria drug hydroxychloroquine
– Studies were halted after research papers claiming that the drug was unsafe were published
– The papers were retracted after the authors were unable to verify data allowing the trials to resume
Global trials of the anti-malaria drug hydroxychloroquine are set to resume under the World Health Organisation (WHO).
The study of the drug had been halted after research papers by respected science journalists were retracted. The papers were withdrawn by the New England Journal and Lancet after the authors could not verify some of the data used in the analysis of the drug
Briefly.co.za learned that South Africa is set to enrol its first patients into the International Solidarity Trial.
The International Solidarity Trial was halted last month by the WHO.
“There are over 130 trials going on worldwide with hydroxychloroquine for COVID-19. Many of those studies were temporarily stopped and the WHO suspended the hydroxychloroquine arm of the solidarity study,” said Solidarity Trial Co-principal investigator, Professor Helen Rees.
She revealed that the drug trials were about to resume in South Africa according to ENCA.
“The Solidarity trial has now received approval from the regulatory authority, SAHPRA, and is now in the final stages of discussion with the ethics committees, but I think that those will come through quite soon. So we are very much hoping that the solidarity study will be able to start within the next one to two weeks.”
The World Health Organisation has released the newest information regarding the use of face masks during the Covid-19 pandemic.
The organisation revealed that wearing a mask alone is not enough to effectively safeguard against the virus.
With global infections now sitting at over 6.8 million and fatalities rising to 398 000 while over 3.3 million people have managed to recover.
Credit: BRIEFLY (SOUTH AFRICA)